Day: November 29, 2022

New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. Recent clinical data for CAN-3110 and CAN-2409 in high-grade glioma to be presented. Scientific rationale for the recently announced collaboration with the University of Pennsylvania using Candel’s enLIGHTEN™ discovery platform to be discussed. Premier experts and thought leaders in immunology and oncology to share perspectives on broad, potential, therapeutic combination synergies and growing opportunity for Candel’s novel viral immunotherapies.NEEDHAM, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies,...

MELBOURNE, Australia, Nov. 29, 2022 (GLOBE NEWSWIRE) — Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific (‘Eurofins’) to manufacture ReneCann therapeutic for topical applications. ReneCann is Incannex’s proprietary topical cannabinoid formulation for treatment of dermatological conditions caused by disorders of the immune system, including vitiligo, psoriasis, and atopic dermatitis, otherwise known as eczema. The ReneCann formulation is commercially protected by granted and pending patents acquired by Incannex as part of the APIRx acquisition...

New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab (BAVENCIO®) Expansion into urothelial cancer builds on core strategy to increase target indications for combination approaches with efti to exploit the full potential of this unique LAG-3 candidate First patient is expected to be enrolled and dosed in H1 of calendar year 2023SYDNEY, AUSTRALIA, Nov. 29, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement (“Agreement”) with Merck KGaA, Darmstadt,...

BOSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) — SeaChange International, Inc. (NASDAQ: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging FAST (Free Ad-Supported Streaming TV services) development, will hold a conference call on Monday, December 12, 2022 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended October 31, 2022. Financial results will be issued in a press release prior to the call. SeaChange management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions in advance of the conference call by emailing SEAC@GatewayIR.com Date: Monday, December 12, 2022Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) U.S. dial-in number: 877-407-8037International number: +1 201-689-8037Meeting...

SANTA ANA, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) announced today that Christopher D. Wampler, vice president, chief financial officer, controller and treasurer, and Suman Mookerji, vice president of corporate development and investor relations, will participate in the upcoming Truist Securities Industrial and Services Summit on December 6th, 2022.   Institutional investors are welcome to contact Truist Securities to arrange one-on-one meetings with management. About Ducommun Incorporated Ducommun Incorporated delivers value-added innovative products and manufacturing solutions to customers in the aerospace, defense and industrial markets. Founded in 1849, the Company specializes in two core areas – Electronic Systems and Structural Systems – to produce...

Virtualized and Orchestrated Products Support the Dynamic Needs of Today’s Software-Defined Payloads and Multi-Orbit Constellations SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider announced today the general availability of its virtual OpenSpace Channelizer and Combiner for satellite ground operations. The products are used to split and combine digitized RF signals for more effective downlink and uplink, especially to support the advanced capabilities of next generation software-defined satellites and LEO constellations.   For example, to support increasing customer demand or to address potential cases of interference, a high bandwidth signal from a software-defined satellite can be split into smaller signals and routed across...

INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD conference in San Francisco November 29th to December 2nd Boca Raton, Florida, Nov. 29, 2022 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will participate in the 15th CTAD Conference in San Francisco November 29th to December 2nd. “This year’s CTAD is showcasing a potential approvable therapy for the treatment of Alzheimer’s Disease (AD) that targets amyloid,” said RJ Tesi MD, CEO of INmune.  “While anti-amyloid therapies may slow the rate of cognitive decline, we believe the goal for AD therapy should be to stop progression of the disease.  This will require the incorporation...

Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs. In this role, Ms. Levin will be in charge of guiding the implementation and regulatory, clinical trial and quality initiatives that are related to in vitro diagnostics. She will contribute to key milestones for the FDA submission process for ColoAlert, the Company’s highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC). She will also be responsible...